MedPacto announced on November 19 that its new immuno-oncology therapy (MP010) has been selected as a final candidate for support in the "Second Round of National New Drug Development Projects for 2025," overseen by the National New Drug Development Project Group.
MedPacto has been chosen for the non-clinical development category in the "New Drug R&D Ecosystem Establishment Research Field" under this project and will receive research and development funding for approximately two years.
MP010 is a first-in-class innovative new drug candidate that selectively binds to 'EDB-FN', which is overexpressed in the tumor microenvironment (TME), and simultaneously targets 'TGF-β', a key regulator in the TME that drives immune evasion and metastasis in cancer.
In animal studies, MedPacto confirmed that MP010 alone achieved high complete response (CR) rates, long-term survival rates, and immune memory effects in difficult-to-treat cancers such as pancreatic cancer and triple-negative breast cancer.
With the selection of this project, MedPacto plans to accelerate the approval of the investigational new drug (IND) application for MP010 and initiate early clinical development in earnest. In particular, MP010 is being evaluated as a next-generation immuno-oncology therapy capable of overcoming the limitations of existing treatments, and discussions on joint research and technology transfer with global pharmaceutical companies are actively underway.
A MedPacto representative stated, "MP010 is one of our core pipelines, and based on this national project selection, we will swiftly enter clinical trials next year and do our utmost to achieve early technology out-licensing."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
